Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.61 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.55 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.50 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1590642 | 0.93 | POLB (0.60) | POLBGRM2KCNQ2GAAROCK1 | |
| SCHEMBL13047106 | 0.93 | POLB (0.51) | POLBGRM2KCNQ2GAAROCK1 | |
| SCHEMBL13046655 | 0.90 | GRM2 (0.55) | POLBGRM2KDM4ECYP3A4CYP2C9 | |
| SCHEMBL13047083 | 0.90 | GRM2 (0.53) | POLBGRM2KCNQ2GAAP2RX7 | |
| SCHEMBL13047079 | 0.87 | P2RX7 (0.51) | POLBGAAP2RX7PARP14KDM4E | |
| SCHEMBL1590676 | 0.87 | P2RX7 (0.62) | POLBGRM2KCNQ2GAAROCK1 | |
| SCHEMBL13047081 | 0.87 | P2RX7 (0.52) | POLBGRM2KCNQ2P2RX7KDM4E | |
| SCHEMBL15290185 | 0.87 | ALDH1A1 (0.50) | GRM2KDM4EHPGDALDH1A1 | |
| SCHEMBL13047124 | 0.87 | ALDH1A1 (0.50) | GRM2KDM4EHPGDALDH1A1 | |
| SCHEMBL13047557 | 0.86 | POLB (0.61) | POLBGRM2KCNQ2GAAROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546579-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | EVOTEC (US) INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546579-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | EVOTEC (US) INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20100292235-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | SECOND GENOME, INC. | 2010-11-18 | — | — | US | disclosed |
| US-20100292235-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | SECOND GENOME, INC. | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292235-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | POLB 3676/4885GRM2 332/4885KCNQ2 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.